MedTrace Logo

Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy

NCT01760616 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 790

Last updated 2020-03-06

No results posted yet for this study

Summary

To evaluate the efficacy and safety of Huaier Granule for prevention of disease progression of hepatocarcinoma after non-radical hepatectomy.

Conditions

  • Hepatic Carcinoma

Interventions

DRUG

Huaier Granule

Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    collaborator OTHER

  • Qidong Gaitianli Medicines Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Xiaoping Chen, Professor · Huazhong University of Science and Technology

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-07
Primary Completion
2015-08-15
Completion
2017-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01760616 on ClinicalTrials.gov